Update on pertussis in children

Expert Review of Anti-Infective Therapy

Volumn 8, Issue 2, 2010, Pages 163-173

  Heininger, Ulrich ^a  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

acellular; Bordetella pertussis; complication; disease; epidemiology; pertussis; prevention; vaccine

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; DIPHTHERIA PERTUSSIS TETANUS VACCINE; ERYTHROMYCIN; PERTUSSIS VACCINE; STEROID; BORDETELLA VIRULENCE FACTOR;

ACTIVE IMMUNIZATION; ANTIBIOTIC PROPHYLAXIS; BACTERIAL VIRULENCE; BACTERIUM CULTURE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATION; BORDETELLA PARAPERTUSSIS; BORDETELLA PERTUSSIS; CLINICAL FEATURE; DISEASE DURATION; HUMAN; NONHUMAN; PATIENT ASSESSMENT; PERTUSSIS; POLYMERASE CHAIN REACTION; PYLORUS STENOSIS; REVIEW; CHILD; EUROPE; IMMUNIZATION; IMMUNOLOGY; INFANT; MICROBIOLOGY; NEWBORN; PATHOGENICITY; PRESCHOOL CHILD;

BORDETELLA PERTUSSIS; CHILD; CHILD, PRESCHOOL; EUROPE; HUMANS; IMMUNIZATION SCHEDULE; INFANT; INFANT, NEWBORN; PERTUSSIS VACCINE; VIRULENCE FACTORS, BORDETELLA; WHOOPING COUGH;

EID: 77954525041     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.09.124     Document Type: Review

References (98)

1. Shrivastava R, Miller JF. Virulence factor secretion and translocation by Bordetella species. Curr. Opin. Microbiol. 12, 88-93 (2009).
2. Crowcroft NS, Booy R, Harrison T et al. Severe and unrecognised: Pertussis in UK infants. Arch. Dis. Child. 88, 802-806 (2003).
3. Bisgard KM, Pascual FB, Ehresmann KR et al. Infant pertussis: Who was the source? Pediatr. Infect. Dis. J. 23, 985-989 (2004).
4. Bonmarin I, Levy-Bruhl D, Baron S et al. Pertussis surveillance in French hospitals: Results from a 10 year period. Euro. Surveill. 12, 1-8 (2007).
5. Kowalzik F, Barbosa AP, Fernandes VR et al. Prospective multinational study of pertussis infection in hospitalized infants and their household contacts. Pediatr. Infect. Dis. J. 26, 238-242 (2007).
6. Wendelboe AM, Njamkepo E, Bourillon A et al. Transmission of Bordetella pertussis to young infants. Pediatr. Infect. Dis. J. 26, 293-299 (2007).
7. Robert Koch-Institut: Impfempfehlungen der Ständigen Impfkommission am Robert Koch-Institut/Stand Juli 2009. Epidemiol. Bull. 30, 279-298 (2009).
8. Forsyth KD, Wirsing von Konig CH, Tan T, Caro J, Plotkin S. Prevention of pertussis: Recommendations derived from the second Global Pertussis Initiative roundtable meeting. Vaccine 25, 2634-2642 (2007).
9. Heininger U, Stehr K, Schmitt-Grohé S et al. Clinical characteristics of illness caused by Bordetella parapertussis compared with illness caused by Bordetella pertussis. Pediatr. Infect. Dis. J. 13, 306-309 (1994). Classical publication that elucidates the clinical spectrum of pertussis caused by Bordetella parapertussis in comparison with that caused by Bordetella is.
10. Stefanelli P, Mastrantonio P, Hausman SZ, Giuliano M, Burns DL. Molecular characterization of two Bordetella bronchiseptica strains isolated from children with coughs. J. Clin. Microbiol. 35, 1550-1555 (1997).
11. Mazengia E, Silva EA, Peppe JA, Timperi R, George H. Recovery of Bordetella holmesii from patients with pertussis-like symptoms: Use of pulsed-field gel electrophoresis to characterize circulating strains. J. Clin. Microbiol. 38, 2330-2333 (2000).
12. Weyant RS, Hollis DG, Weaver RE et al. Bordetella holmesii sp. nov., a new Gram-negative species associated with septicemia. J. Clin. Microbiol. 33, 1-7 (1995).
13. Spilker T, Liwienski AA, LiPuma JJ. Identification of Bordetella spp. in respiratory specimens from individuals with cystic fibrosis. Clin. Microbiol. Infect. 14, 504-506 (2008).
14. Daxboeck F, Goerzer E, Apfalter P, Nehr M, Krause R. Isolation of Bordetella trematum from a diabetic leg ulcer. Diabet. Med. 21, 1247-1248 (2004).
15. Vandamme P, Heyndrickx M, Vancanneyt M et al. Bordetella trematum sp. nov., isolated from wounds and ear infections in humans, and reassessment of Alcaligenes denitrificans Rüger and Tan 1983. Int. J. System. Bacteriol. 46, 849-858 (1996).
16. Stark D, Riley LA, Harkness J, Marriott D. Bordetella petrii from a clinical sample in Australia: Isolation and molecular identification. J. Med. Microbiol. 56, 435-437 (2007).
17. Cherry JD, Heininger U. Pertussis and other Bordetella infections. In: Textbook of Pediatric Infectious Diseases (6th Edition). Feigin RD, Cherry JD, Demmler-Harrison GJ, Kaplan SL (Eds). WB Saunders, PA, USA, 1683-1706 (2009).
18. Mattoo S, Cherry JD. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin. Microbiol. Rev. 18, 326-382 (2005). Utmost source of information on all aspects of pertussis.
19. Heininger U, Cherry JD, Eckhardt T, Lorenz C, Christenson P, Stehr K. Clinical and laboratory diagnosis of pertussis in the regions of a large vaccine efficacy trial in Germany. Pediatr. Infect. Dis. J. 12, 504-509 (1993). (Pubitemid 23173495)
20. Waters V, Jamieson F, Richardson SE, Finkelstein M, Wormsbecker A, Halperin SA. Outbreak of atypical pertussis detected by polymerase chain reaction in immunized preschool-aged children. Pediatr. Infect. Dis. J. 28, 582-587 (2009).
21. Narkeviciute I, Kavaliunaite E, Bernatoniene G, Eidukevicius R. Clinical presentation of pertussis in fully immunized children in Lithuania. BMC Infect. Dis. 5, 40 (2005).
22. Long S, Lischner H, Deforest A, Clark J. Serologic evidence of subclinical pertussis in immunized children. Pediatr. Infect. Dis. J. 9, 700-705 (1990).
23. Edelman K, Nikkari S, Ruuskanen O, He Q, Viljanen M, Mertsola J. Detection of Bordetella pertussis by polymerase chain reaction and culture in the nasopharynx of erythromycin-treated infants with pertussis. Pediatr. Infect. Dis. J. 15, 54-57 (1996).
24. Cherry JD, Brunell PA, Golden GS, Karzon DT. Report of the task force on pertussis and pertussis immunization -1988. Pediatrics. 81(Suppl.), 939-984 (1988).
25. Heininger U, Klich K, Stehr K, Cherry JD. Clinical findings in Bordetella pertussis infections: Results of a prospective multicenter surveillance study. Pediatrics 100(6), E10 (1997).
26. Halasa NB, Barr FE, Johnson JE, Edwards KM. Fatal pulmonary hypertension associated with pertussis in infants: Does extracorporal membrane oxygenation have a role? Pediatrics 112, 1274-1278 (2003).
27. Surridge J, Segedin ER, Grant CC. Pertussis requiring intensive care. Arch. Dis. Child. 92, 970-975 (2007).
28. Heininger U, Stehr K, Schmidt-Schläpfer G et al. Bordetella pertussis infections and sudden unexpected deaths in children. Eur. J. Pediatr. 155, 551-553 (1996).
29. Lindgren C, Milerad J, Lagercrantz H. Sudden infant death and prevalence of whooping cough in the Swedish and Norwegian communities. Eur. J. Pediatr. 156, 405-409 (1997).
30. Crowcroft NS, Andrews N, Rooney C, Brisson M, Miller E. Deaths from pertussis are underestimated in England. Arch. Dis. Child. 86, 336-338 (2002).
31. Wood N, McIntyre P. Pertussis: Review of epidemiology, diagnosis, management and prevention. Paediatr. Respir. Rev. 9, 201-211 (2008).
32. Wirsing Von König CH, Rott H, Bogaerts H, Schmitt HJ. A serologic study of organisms possibly associated with pertussis-like coughing. Pediatr. Infect. Dis. J. 17, 645-649 (1998).
33. Edelman K, Nikkari S, Ruuskanen O, He Q, Viljanen M, Mertsola J. Detection of Bordetella pertussis by polymerase chain reaction and culture in the nasopharynx of erythromycin-treated infants with pertussis. Pediatr. Infect. Dis. J. 15, 54-57 (1996).
34. Heininger U, Frei R, Cherry JD, Stehr K. Comparison of pulsed field gel electrophoresis patterns of Bordetella pertussis isolates from unvaccinated children with severe or mild pertussis. Pediatr. Infect. Dis. J. 23, 211-217 (2004).
35. Bartkus JM, Juni BA, Ehresmann K et al. Identification of a mutation associated with erythromycin resistance in Bordetella pertussis: Implications for surveillance of antimicrobial resistance. J. Clin. Microbiol. 41, 1167-1172 (2003).
36. Fry NK, Duncan J, Wagner K et al. Role of PCR in the diagnosis of pertussis infection in infants: 5 years' experience of provision of a same-day real-time PCR service in England and Wales from 2002 to 2007. J. Med. Microbiol. 58, 1023-1029 (2009).
37. Heininger U, Schmidt-Schläpfer G, Cherry JD, Stehr K. Clinical validation of a polymerase chain reaction assay for the diagnosis of pertussis by comparison with serology, culture, and symptoms during a large pertussis vaccine efficacy trial. Pediatrics 105(3), E31 (2000).
38. Cherry JD, Grimprel E, Guiso N, Heininger U, Mertsola J. Defining pertussis epidemiology: Clinical, microbiologic and serologic perspectives. Pediatr. Infect. Dis. J. 24, S25-S34 (2005).
39. Meade BD, Bollen A. Recommendations for use of the polymerase chain reaction in the diagnosis of Bordetella pertussis infections. J. Med. Microbiol. 41, 51-55 (1994).
40. Baughman AL, Bisgard KM, Edwards KM et al. Establishment of diagnostic cutoff points for levels of serum antibodies to pertussis toxin, filamentous hemagglutinin, and fimbriae in adolescents and adults in the United States. Clin. Diagn. Lab. Immunol. 11, 1045-1053 (2004).
41. Bonhoeffer J, Bar G, Riffelmann M, Soler M, Heininger U. The role of Bordetella infections in patients with acute exacerbation of chronic bronchitis. Infection 33, 13-7 (2005).
42. Wirsing von König CH, Gounis D, Laukamp S, Bogaerts H, Schmitt HJ. Evaluation of a single-sample serological technique for diagnosing pertussis in unvaccinated children. Eur. J. Clin. Microbiol. Infect. Dis. 18, 341-345 (1999). Publication of practical relevance which describes how a serological diagnosis of pertussis can be made in a single serum specimen.
43. Romano MJ, Weber MD, Weisse ME, Siu BL. Pertussis pneumonia, hypoxemia, hyperleukocytosis, and pulmonary hypertension: Improvement in oxygenation after a double volume exchange transfusion. Pediatrics 114, e264-e266 (2004).
44. Sawal M, Cohen M, Irazuzta JE et al. Fulminant pertussis: A multi-center study with new insights into the clinico-pathological mechanisms. Pediatr. Pulmonol. 44, 970-980 (2009). Provides insight in pathological findings by autopsy in fatal cases of pertussis.
45. Zoumboulakis D, Anagnostakis D, Albanis V, Matsaniotis. Steroids in treatment of pertussis -a controlled clinical trial. Arch. Dis. Child. 48, 51-54 (1973).
46. Tam AY, Yeung CY. Severe neonatal pertussis treated by salbutamol. Arch. Dis. Child. 61, 600-602 (1986).
47. Hoppe JE. State of art in antibacterial susceptibility of Bordetella pertussis and antibiotic treatment of pertussis. Infection 26, 242-246 (1998). Classical publication on the spectrum of antibiotics that can be used for treatment of pertussis; still relevant today.
48. Korgenski EK, Daly JA. Surveillance and detection of erythromycin resistance in Bordetella pertussis isolates recovered from a pediatric population in the Intermountain West region of the United States. J. Clin. Microbiol. 35, 2989-2991 (1997).
49. Aoyama T, Sunakawa K, Iwata S, Takeuchi Y, Fujii R. Efficacy of short-term treatment of pertussis with clarithromycin and azithromycin. J. Pediatr. 129, 761-764 (1996).
50. Langley JM, Halperin SA, Boucher FD, Smith B, Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC). Azithromycin is as effective as and better tolerated than erythromycin estolate for the treatment of pertussis. Pediatrics 114, e96-e101 (2004).
51. Lebel MH, Mehra F, Mehra S. Efficacy and safety of clarithromycin versus erythromycin for the treatment of pertussis: A prospective, randomized, single blind trial. Pediatr. Infect. Dis. J. 20, 1149-1154 (2001).
52. Hoppe JE and the Erythromycin Study Group. Comparison of erythromycin estolate and erythromycin ethylsuccinate for treatment of pertussis. Pediatr. Infect. Dis. J. 11, 189-193 (1992).
53. Bass JW, Harden LB. Treatment and prophylaxis failure of erythromyin in pertussis. Am. J. Dis. Child. 134, 1178-1179 (1980).
54. Halperin SA, Bortolussi R, Langley JM, Miller B, Eastwood BJ. Seven days of erythromycin estolate is as effective as fourteen days for the treatment of Bordetella pertussis infections. Pediatrics 100, 65-71 (1997).
55. Aoyama T, Sunakawa K, Iwata S, Takeuchi Y, Fujii R. Efficacy of short-term treatment of pertussis with clarithromycin and azithromycin. J. Pediatr. 129, 761-764 (1996).
56. Centers for Disease Control. Hypertrophic pyloric stenosis in infants following pertussis prophylaxis with erythromycin -Knoxville, Tennessee, 1999. MMWR 48, 1117-1120 (1999).
57. Honein MA, Paulozzi LJ, Himelright IM et al. Infantile hypertrophic pyloric stenosis after pertussis prophylaxis with erythromycin: A case review and cohort study. Lancet 354, 2101-2105 (1999).
58. Morrison W. Infantile hypertrophic pyloric stenosis in infants treated with azithromycin. Pediatr. Infect. Dis. J. 26, 186-188 (2007).
59. Hoppe J, Halm U, Hagedorn H, Kraminer-Hagedorn A. Comparison of erythromycin ethylsuccinate and co-trimoxazole for treatment of pertussis. Infection 17, 227-231 (1989).
60. Dodhia H, Crowcroft NS, Bramley JC, Miller E. UK guidelines for use of erythromycin chemoprophylaxis in persons exposed to pertussis. J. Public Health Med. 24, 200-206 (2002).
61. De Serres G, Boulianne N, Duval B. Field effectiveness of erythromycin prophylaxis to prevent pertussis within families. Pediatr. Infect. Dis. J. 14, 969-975 (1995).
62. Halperin SA, Bortolussi R, Langley JM, Eastwood BJ, De Serres G. A randomized, placebo-controlled trial of erythromycin estolate chemoprophylaxis for household contacts of children with culture-positive Bordetella pertussis infection. Pediatrics 104(4), e42 (1999).
63. Crameri S, Heininger U. Successful control of a pertussis outbreak in a university children's hospital. Int. J. Infect. Dis. 12, e85-e87 (2008).
64. Tozzi AE, Pandolfi E, Celentano LP et al. Comparison of pertussis surveillance systems in Europe. Vaccine 25, 291-297(2007).
65. Ward JI, Cherry JD, Chang SJ et al. Efficacy of an acellular pertussis vaccine among adolescents and adults. N. Engl. J. Med. 353, 1555-1563 (2005). The only study until today which demonstrated acellular pertussis vaccine efficacy in adults.
66. Long S, Welkon C, Clark J. Widespread silent transmission of pertussis in families: Antibody correlates of infection and symptomatology. J. Infect. Dis. 161, 480-486 (1990).
67. Anderson RM, May RM. Immunisation and herd immunity. Lancet 335(8690), 641-645 (1990).
68. Forsyth KD, Campins-Marti M, Caro J et al. New pertussis vaccination strategies beyond infancy: Recommendations by the global pertussis initiative. Clin. Infect. Dis. 39, 1802-1809 (2004).
69. Cherry JD, Baraff LJ, Hewlett E. The past, present, and future of pertussis. The role of adults in epidemiology and future control. West. J. Med. 150, 319-328 (1989).
70. Cherry JD, Grimprel E, Guiso N, Heininger U, Mertsola J. Defining pertussis epidemiology: Clinical, microbiologic and serologic perspectives. Pediatr. Infect. Dis. J. 24, S25-S34 (2005).
71. Pebody RG, Gay NJ, Giammanco A et al. The seroepidemiology of Bordetella pertussis infection in Western Europe. Epidemiol. Infect. 133, 159-171 (2005).
72. Rota MC, D'Ancona F, Massari M et al. How increased pertussis vaccination coverage is changing the epidemiology of pertussis in Italy. Vaccine 23, 5299-5305 (2005).
73. Hellenbrand W, Beier D, Jensen E et al. The epidemiology of pertussis in Germany: Past and present. BMC Infect. Dis. 25, 22 (2009).
74. Cherry JD. Epidemiological, clinical, and laboratory aspects of pertussis in adults. Clin. Infect. Dis. 28 (Suppl. 2), S112-S117 (1999).
75. Hennes H. Der Keuchhusten bei Erwachsenen. Med. Klinik. 17, 591-593 (1921).
76. Nelson JD. The changing epidemiology of pertussis in young infants: The role of adults as reservoirs of infection. Am. J. Dis. Child. 132, 371-373 (1978).
77. Mortimer EA. Pertussis and its prevention: A family affair. J. Infect. Dis. 161, 473-479 (1990).
78. Heininger U, Stehr K, Christenson P, Cherry JD. Evidence of efficacy of the Lederle/Takeda acellular pertussis component diphtheria and tetanus toxoids and pertussis vaccine but not the Lederle whole-cell component diphtheria and tetanus toxoids and pertussis vaccine against Bordetella parapertussis infection. Clin. Infect. Dis.28, 602-604 (1999).
79. Trollfors B, Taranger J, Lagergard T et al. A placebo-controlled trial of a pertussis-toxoid vaccine. N. Engl. J. Med. 333, 1045-1050 (1995).
80. Greco D, Salmaso S, Mastrantonio P et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N. Engl. J. Med. 334, 341-348 (1996).
81. Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsaeter J. A controlled trial of a two-component acellular, a five-component acellular and a whole-cell pertussis vaccine. N. Engl. J. Med. 334, 349-355 (1996).
82. Schmitt HJ, Wirsing von König CH, Neiss A et al. Efficacy of acellular pertussis vaccine in early childhood after household exposure. JAMA. 275, 37-41 (1996).
83. Simondon F, Preziosi MP, Yam A et al. A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal. Vaccine 15, 1606-1612 (1997).
84. Liese JG, Meschievitz CK, Harzer E et al. Efficacy of a two-component acellular pertussis vaccine in infants. Pediatr. Infect. Dis. J. 16, 1038-1044 (1997).
85. Stehr K, Cherry JD, Heininger U et al. A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine or DT vaccine. Pediatrics 101, 1-11 (1998). (Pubitemid 28030315)
86. Heininger U, Cherry JD. Pertussis immunisation in adolescents and adults -Bordetella pertussis epidemiology should guide vaccination recommendations. Expert. Opin. Biol. Ther. 6, 685-697 (2006). Complements this review owing to its specific focus on adolescents and adults.
87. Collins CL, Salt P, McCarthy N et al. Immunogenicity and safety of a low-dose diphtheria, tetanus and acellular pertussis combination vaccine with either inactivated or oral polio vaccine as a pre-school booster in UK children. Vaccine 22, 4262-4269 (2004).
88. Minh NN, He Q, Ramalho A et al. Acellular vaccines containing reduced quantities of pertussis antigens as a booster in adolescents. Pediatrics 104, e70 (1999).
89. Cherry JD. 'Pertussis vaccine encephalopathy': It is time to recognize it as the myth that it is. JAMA 263, 1679-1680 (1990). Concise summary on the issue of the nonexistence of a causal relationship between pertussis immunization and encephalopathy.
90. Heininger U, Zuberbühler M. Immunization rates and timely administration in pre-school and school-aged children. Eur. J. Pediatr. 165, 124-129 (2006).
91. Elomaa A, He Q, Minh NN, Mertsola J. Pertussis before and after the introduction of acellular pertussis vaccines in Finland. Vaccine 27, 5443-5449 (2009).
92. Juretzko P, von Kries R, Hermann M, Wirsing von König CH, Weil J, Giani G. Effectiveness of acellular pertussis vaccine assessed by hospital-based active surveillance in Germany. Clin. Infect. Dis. 35, 162-167 (2002).
93. Heininger U, Cherry JD, Stehr K et al. Comparative efficacy of the Lederle/Takeda acellular pertussis component DTP (DTaP). vaccine and Lederle whole-cell component DTP vaccine in German infants following household exposure. Pediatrics 102, 546-553 (1998). (Pubitemid 28409252)
94. Halasa NB, O'Shea A, Shi JR, LaFleur BJ, Edwards KM. Poor immune responses to a birth dose of diphtheria, tetanus, and acellular pertussis vaccine. J. Pediatr. 153, 327-332 (2008).
95. Knuf M, Schmitt HJ, Wolter J et al. Neonatal vaccination with an acellular pertussis vaccine accelerates the acquisition of pertussis antibodies in infants. J. Pediatr. 152, 655-660 (2008). Shows that newborns can be immunized effectively against pertussis.
96. Heininger U, Cherry JD, Christenson P et al. Comparative study of Lederle/Takeda acellular and whole-cell pertussis component diphtheria-tetanus- pertussis vaccines in infants in Germany. Vaccine 12, 81-86 (1994).
97. Van Rie A, Wendelboe AM, Englund JA. Role of maternal pertussis antibodies in infants. Pediatr. Infect. Dis. J. 24(Suppl.), S62-S65 (2005).
98. de La Rocque F, Grimprel E, Gaudelus J et al. Vaccination in parents of young infants survey. Arch. Pediatr. 14, 1472-1476 (2007).